WO2008015793A1 - appareil augmentant le facteur neurotrophe lié au cerveau et procédé visant à augmenter le facteur neurotrophe lié au cerveau - Google Patents

appareil augmentant le facteur neurotrophe lié au cerveau et procédé visant à augmenter le facteur neurotrophe lié au cerveau Download PDF

Info

Publication number
WO2008015793A1
WO2008015793A1 PCT/JP2007/000830 JP2007000830W WO2008015793A1 WO 2008015793 A1 WO2008015793 A1 WO 2008015793A1 JP 2007000830 W JP2007000830 W JP 2007000830W WO 2008015793 A1 WO2008015793 A1 WO 2008015793A1
Authority
WO
WIPO (PCT)
Prior art keywords
brain
voltage
neurotrophic factor
derived neurotrophic
living body
Prior art date
Application number
PCT/JP2007/000830
Other languages
English (en)
Japanese (ja)
Inventor
Hiroji Yanamoto
Original Assignee
Hiroji Yanamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroji Yanamoto filed Critical Hiroji Yanamoto
Priority to JP2008527659A priority Critical patent/JP5272164B2/ja
Publication of WO2008015793A1 publication Critical patent/WO2008015793A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents

Definitions

  • the present invention relates to a brain-derived neurotrophic factor increasing device and a brain-derived neurotrophic factor increasing method using an AC voltage having a specific voltage value.
  • BDN F brain-derived neurotrophic factor
  • BDNF brain-derived neurotrophic factor
  • BDN F is thought to contribute to synaptic plasticity and memory by promoting the differentiation of endogenous neural stem cells into neurons and the growth of neurites of immature or mature neurons.
  • an increase in BDN F increases the viability of immature or mature neurons.
  • BDN F is abnormally lowered in the brain, immature neurons, impaired neuronal differentiation, mature neurons, neuronal regression and neurites and synapses, and brain atrophy and nerves due to them Decreased functions, etc. may cause memory loss, depression, depressive mood disorder, or cognitive (dementia) disease (see Non-Patent Document 2).
  • Non-Patent Document 3 More recently, antidepressants used for depression and depressive mood injuries have been shown to increase BDN F levels in the brain, which leads to a decrease in brain BDN F levels. It causes depression, depressive mood disorders, and various physical symptoms resulting from them, which are thought to be ameliorated by increasing BDN F levels in the brain. (See Non-Patent Document 3).
  • BDN F does not pass through the blood-brain barrier, it is not taken into the brain from the blood. Therefore, even if BDN F is administered orally or intravenously, It has been thought that the function is not performed.
  • administration of B DN F (1 Omg / kg / day) by subcutaneous injection for a certain period (1 week) works on glucose metabolism, that is, production or secretion of glucagon from cells in the pancreas, thus lowering blood glucose. It became clear that the effect was shown (refer nonpatent literature 4).
  • BDNF increases by exposing a living body to a high voltage or placing it in a high electric field, and previously proposed a method of producing an in vivo neurotrophic factor using an alternating high potential.
  • Patent Document 5 See Patent Document 5.
  • BDNF is increased in the living body for a certain period of time, but the effect is not necessarily maintained and the effect is eventually reduced.
  • Patent Document 1 Japanese Patent Laid-Open No. 58-146361
  • Patent Document 2 JP-A-7-284535
  • Patent Document 3 Japanese Patent Laid-Open No. 2000_42 1 23
  • Patent Document 4 Japanese Unexamined Patent Publication No. 2003 _ 1 26270
  • Patent Document 5 P CT / J P 2005/1 7 1 77
  • Non-patent document 1 Naoki Miura et al., “Antihypertensive effect on hypertension model animals (D a h I _S rats) of alternating high voltage potential”, Journal of the Japan Veterinary Medical Association, 2001, 54, p 472_475
  • Non-Patent Document 2 Fossati P et al., “Neuroplasticity: frm MRI todepressives ym pt om s”, Yoropi, N-nu European N europsychophar ma cology 2004, 14-S5, p.S503-S5 1 0
  • Non-patent document 3 K hundakar A et al., “Biphasicchangein BD ⁇ ⁇ - gene-expression foll ow ingantidepressantdrug, which can be explained by different transcriptional regulation, after antidepressant treatment a I transcriptregulation), B rain Research, 2006, 1 1 06, p. 1 2-20
  • Non-Patent Document 4 Hanyu et al., “Brain— derived neurotrophicfa ctor mo dulates glucagons secre tionfr om pancreatic alphaeel I s: itscontributiontogluc osemetaboli sm) ”, Diversity (Diabetes O be s. Meta b.), 2003, Volume 5, p. 27-37
  • Non-Patent Document 5 Xu B et al., “Brain _d erivedneurotrophicfac torregulates energybal ances ow nstre am ofme I annocortin— 4 receptor” ”Nichiya ⁇ New Rosaiens (Nat. N eurosc), 2003, Vol. 6, p. 65 5-656
  • the viability inherent in the nerve cells will increase over a long period of time, leading to ischemic diseases and physical It can protect the nerve for a long time from various stresses that may cause nerve injury such as injury.
  • the neurite outgrowth promoting effect and new synapse formation it restores lost cranial nerve function, prevents and improves dementia with a decline in memory ability, and memory ability in a normal state It becomes possible to improve the cranial nerve function of a long term.
  • depression and various symptoms of the body caused by depression are prevented and improved. Obesity, which causes urine, hypertension, stroke, heart disease, hyperlipidemia, gout, etc., can be expected to prevent and improve metabolic syndrome.
  • a healthy person or a patient at risk of suffering from ischemic disease a patient who is already suffering from ischemic disease, neurodegenerative disease, cranial nerve dysfunction due to trauma or other causes, or cranial nerve function such as memory ability It can be used on a daily basis for patients with dementia, etc., whose nerves have decreased, and protects nerve cells from various disorders continuously for a long period of time, improving nerve function, and depression, depressive mood disorders Obesity caused by overeating and lack of exercise by preventing or ameliorating various symptoms based on them, or suppressing excessive appetite or reducing hyperglycemia in the blood, Alternatively, it has been desired to develop a method for continuously increasing in vivo neurotrophic factor that can prevent and / or improve metapolytic syndrome.
  • the present invention has been made to solve such problems, and includes a method for increasing neurotrophic factor capable of continuously increasing brain-derived neurotrophic factor in a living body over a long period of time, and An object is to provide a neurotrophic factor increasing device.
  • the present invention relates to a voltage generating means for generating an alternating voltage having a specific voltage value, and a brain-derived nerve in the living body by applying the alternating voltage generated by the voltage generating means to the living body.
  • An apparatus for increasing brain-derived neurotrophic factor comprising: an energizing means for increasing a trophic factor.
  • the energizing means is also filled with a first material having fluidity of 0.0 1 to 2 S / m at a frequency of 1 Hz to 1 OOH z.
  • the brain-derived neurotrophic factor increasing device further comprising a temperature control unit that controls the temperature of the first material.
  • a temperature control unit that controls the temperature of the first material.
  • the temperature control unit controls the temperature of the first material to 4 to 45 ° C. It is an increase device.
  • the energizing means is made of a non-flowable second material having a conductivity of 0.001 to 2 S / m at a frequency of 1 Hz to 1 OOH z.
  • the brain-derived neurotrophic factor increasing device according to (1) characterized in.
  • the present invention is also characterized in that the energizing means is made of a third material having a conductivity lower than that of the first material at least in a portion in contact with the living body.
  • the present invention is also characterized in that the energizing means is made of a third material having a conductivity lower than that of the second material at least in a portion in contact with the living body. 5.
  • the present invention also provides that the third material has an electrical resistance value of 1 O kQ / cm 2 or more, and is derived from the brain according to (6) or (7) It is a neurotrophic factor increasing device.
  • the energizing means is a chair type, a chair cover type, a seat chair type, a seat chair cover type, a regular seat chair type, a regular seat cover type, a seat cushion type, a cushion cover type, Full-body mattress type, Full-body mattress cover type, Headrest type, Headrest cover type, Cushion type, Cushion cover type, Pillow type, Pillow cover type, Auxiliary pillow type, Auxiliary pillow cover type, Upper body pillow type,
  • the brain-derived neuronutrition according to any one of (1) to (8), characterized in that it has the shape of an upper body pillow cover type, a body pillow type, a body pillow cover type, a bed type or a sofa type It is a factor increasing device.
  • the energizing means extends the thoracic spine peripheral flexor muscle group of the living body in the supine position of the living body, and does not involve the dorsiflexion of the head and neck transition portion of the living body.
  • the brain-derived neurotrophic factor according to any one of (1) to (9), characterized in that it has a shape of an upper body pillow or upper body pillow cover that can raise the body from the bottom surface It is an increase device.
  • the energizing means is a pillow type that can support the rear neck of the living body and raise the upper chest lightly from the neck while supporting the living body in the supine position.
  • the brain-derived neurotrophic factor increasing device according to any one of (1) to (1 0), characterized by having a pillow cover shape.
  • the present invention further includes a voltage electric field measuring means for measuring an effective applied voltage value or an effective applied electric field value of an AC voltage actually applied to a living body by the energizing means,
  • the brain-derived neurotrophic factor increasing device according to any one of (1) to (11).
  • the present invention is also such that the energizing means has an effective applied voltage value of 3.5 to 5.2 kV, or an effective applied electric field value of 15 to 22 kV / m.
  • the brain according to any one of (1) to (1 2), characterized in that it is used to improve the cranial nerve function, improve memory ability, or prevent and improve dementia. It is a derived neurotrophic factor increasing device.
  • the energization means may be configured so that an effective applied voltage value is 3.5 to 5.2 kV, or an effective applied electric field value is 15 to 22 kV / m.
  • an AC voltage is applied to the device and used for the treatment of ischemic brain injury. is there.
  • the energization means may be configured so that an effective applied voltage value is 3.5 to 5.2 kV, or an effective applied electric field value is 15 to 22 kV / m. Any one of (1) to (1 2) is used to improve motivation, depression, depressive mood disorders, or various symptoms based on them.
  • the energization means may be configured so that an effective applied voltage value is 3.5 to 5.2 kV, or an effective applied electric field value is 15 to 22 kV / m.
  • the brain-derived nerve according to any one of (1) to (1 2) characterized in that it is used to apply an AC voltage to the body, and is used for appetite suppression or prevention and improvement of obesity or metapolitic syndrome. It is a trophic factor increasing device.
  • the energization means may be configured so that an effective applied voltage value is 3.5 to 4.3 kV, or an effective applied electric field value is 15 to 19 kV / m.
  • the apparatus for increasing brain-derived neurotrophic factor according to any one of (1) to (1 2) characterized in that an AC voltage is applied to the device and used to improve hyperglycemia or glucose metabolism. is there.
  • the present invention also provides a voltage generation step for generating an AC voltage having a specific voltage value, and an AC voltage generated by the voltage generation step is applied to the living body, so that the brain-derived nerve in the living body
  • a method for increasing brain-derived neurotrophic factor comprising: an energization step for increasing a trophic factor.
  • the present invention further includes a voltage electric field measurement step of measuring an effective applied voltage value or an effective applied electric field value of the alternating voltage actually applied to the living body through the energization step.
  • the method for increasing brain-derived neurotrophic factor according to (18).
  • the energization step may be performed so that an effective applied voltage value is 3.9 to 4.7 kV, or an effective applied electric field value is 17 to 21 kV / m.
  • AC voltage is applied to improve cranial nerve function, improve memory ability or prevent and improve dementia, treat ischemic brain damage, decrease motivation, depression, depressive mood disorders or symptoms based on them
  • the energization step may be performed so that the effective applied voltage value is 3.5 to 4.3 kV, or the effective applied electric field value is 15 to 19 kV / m.
  • the brain-derived neurotrophic factor according to any one of (1 8) or (1 9), wherein an AC voltage is applied to the blood and used to improve hyperglycemia or glucose metabolism. It is an increase method.
  • the brain-derived neurotrophic factor increasing device and the brain-derived neurotrophic factor increasing method of the present invention in order to increase the brain-derived neurotrophic factor in the living body by applying an alternating voltage having a specific voltage value to the living body, it is possible to continuously increase the brain-derived neurotrophic factor in the living body over a long period of time. it can.
  • the brain-derived neurotrophic factor increasing device and the brain-derived neurotrophic factor increasing method of the present invention it is possible to continuously increase the brain-derived neurotrophic factor in a living body for a long period of time. The following effects can be obtained.
  • the brain is protected for a long period of time from cerebral ischemic diseases such as cerebral infarction, neurodegenerative diseases and nerve injury caused by cerebrospinal injury. be able to.
  • cerebral ischemic diseases such as cerebral infarction, neurodegenerative diseases and nerve injury caused by cerebrospinal injury.
  • insomnia easy fatigue, fatigue fatigue, headache, head weight, stiff shoulders, decreased libido, erectile dysfunction, decreased appetite, mustache, constipation, weight loss, feeling hot, numbness, tinnitus, dizziness, Can improve depression, depressive mood disorders, and various symptoms based on them, which are known to show psychosomatic symptoms such as decreased motivation and memory.
  • the body weight can be reduced, and the metapolitic syndrome that causes obesity, diabetes, hypertension, hyperlipidemia, and the like can be prevented and improved.
  • increasing device a brain-derived neurotrophic factor increasing device (hereinafter sometimes simply referred to as “increasing device”) according to an embodiment of the present invention will be described in detail with reference to the drawings.
  • FIG. 1 is a block diagram showing a main configuration of the increase device 10 according to the present embodiment.
  • the increase device 10 has a specific power supply based on the power supplied from the power supply unit 12.
  • Voltage generating means 14 capable of generating an alternating voltage having a pressure value, and an AC voltage generated by the voltage generating means 14 is applied to a living body (for example, a human animal or plant) to generate brain-derived neurotrophic in vivo
  • Current measuring means 16 for increasing the factor
  • voltage measuring means 18 for measuring the effective voltage value of the AC voltage actually applied to the living body by the current supplying means 16 (“effective applied voltage value” to be described later). Configured.
  • the power supply unit 12 is for supplying predetermined power to the increase device 10; for example, an alkaline ion battery, a lithium ion battery, a 100 V AC power supply, a 200 V AC power supply, a battery Solar cells can be applied.
  • a DC power supply may be applied as the power supply unit 12, and in this case, a conversion unit for converting the DC power supply to the AC power supply may be provided between the DC power supply and the increase device 10.
  • the voltage generation means 14 includes an operation unit 20, an ON / OFF switching unit 2 2 that controls supply of power from the power supply unit 12, and a high voltage generation circuit 24. According to the operation input information from the temperature control unit 26 and the operation unit 20 and the pre-stored program, the ON / OFF switching unit 2 2, the high voltage generation circuit 24, and the temperature control unit 26 And a control unit 28 for performing control.
  • the “voltage generating means” according to the present invention is not limited to the configuration shown in the present embodiment, and may be configured to generate an AC voltage having a specific voltage value.
  • Examples of the switch provided in the operation unit 20 include a "power switch” for turning on / off the power supply of the increase device 10 and a “treatment time” for selecting a treatment time by the increase device 10 “Selection switch”, “Voltage value selection switch” for selecting the voltage value output from the increase device 10, “Frequency selection switch” for selecting the frequency of the AC voltage output from the increase device 10, etc.
  • the “treatment time selection switch” controls the ON / OFF switching unit 2 2 by the control unit 28 and the power supply of the increase device 10 is set to OF.
  • the “voltage value selection switch” can be configured to set the effective applied voltage value of the alternating voltage applied to the living body from the energizing means 16 to a predetermined voltage value, for example.
  • the high voltage generation circuit 24 is for generating an AC voltage having a specific voltage value.
  • a transformer or the like can be applied.
  • the AC voltage generated by the high voltage generation circuit 2 4 only needs to contain an AC component, and may be composed of a single AC component or a layer of AC and DC components. May be.
  • the high voltage generation circuit 24 according to the present embodiment is not limited to a transformer.
  • an AC high voltage generation circuit frequently used in a conventional potential treatment device specifically, a predetermined voltage is applied to a living body.
  • An AC voltage necessary for applying an effective applied voltage value can be supplied to the energizing means 16 or the AC voltage can be varied regularly or irregularly within a predetermined voltage value range. It is possible to apply one with a variable function.
  • the temperature control unit 26 performs temperature control such as heating or cooling of the first material, which will be described later, and sets the temperature of the energization unit 16C (see Fig. 2) of the energization means 16 to, for example, 4 to The temperature is controlled in the range of 45 ° C, preferably 18 to 36 ° C so that the living body feels comfortable. As a result, the user can use the increase device 10 comfortably for a long time at the optimum temperature.
  • the temperature control unit 26 does not necessarily have to be provided in the voltage generation unit 14, and the temperature control unit 26 and the voltage generation unit 14 may be configured separately. Further, the temperature control unit 26 does not necessarily have to be provided, and the temperature control unit 26 may be omitted.
  • the control unit 28 is constituted by a CPU or the like, and 0 1 ⁇ 1/0 "" switching unit 2 2, high voltage generation circuit 24, and temperature so that the increase device 1 0 functions normally Controls the control unit 26.
  • FIG. 2 is a diagram showing the energization means 16 in the present embodiment, (A) is a schematic side view thereof, and (B) is a schematic plan view thereof.
  • the energizing means 16 has an upper body pillow shape, and the cable 16 A, an electrode portion 16 B connected to the voltage generating means 14 via this cable 16 A, and an energization portion for applying an AC voltage generated from the electrode portion 16 B in contact with the living body And 1 6 C.
  • the temperature of the first material is adjusted using the temperature control unit 26 described above, and a roller pump or the like (not shown) installed in the temperature control unit 26 is used.
  • the first material is configured to circulate between the temperature control unit 26 and the inside of the energization unit 16 C through a conduit. As a result, the AC voltage can be transmitted to the entire energization means 16 through the first material of the energization section 16 C, and the temperature control of the energization means 16 can be simultaneously performed.
  • the energizing means 16 does not necessarily have to have the electrode part 16 B, but the electrode part is provided in the voltage generating means 14 or in another part, and the first material to be circulated is used.
  • the AC voltage can be applied and transmitted.
  • the first material filled in the energizing section 16 C does not necessarily need to be temperature controlled, and in that case, the circulation mechanism with the temperature control section 26 may be omitted.
  • the first material that can be used in the present invention is not particularly limited as long as it is a liquid having conductivity similar to that of a living body, and for example, 0.0001 to 1.0% of chloride.
  • An ion-containing solution such as sodium (N a CI) can be used.
  • N a CI sodium
  • various materials can be used regardless of the conductivity.
  • the current-carrying part 16 C instead of filling the inside of the current-carrying part 16 C with the first material, the current-carrying part 16 C has a dielectric constant similar to that of a living body (0.001 to 2 S / m (frequency 1 H z to 10 OH z, 18 to 25 ° C.)), and may be composed of a non-flowable second material.
  • second material include gels containing ions such as 0.0001 to 1.0% sodium chloride (N a CI), synthetic rubbers having the above dielectric constant, low-rebound polyurethane or bead mats. Etc.
  • the insulation between the living body and the surrounding environment is insufficient. Discharge is likely to occur between the body and the surface of the living body, and this discharge has locally given unpleasant pain to the user.
  • a material having a bio-like conductivity is applied to the energizing portion 16 C of the energizing means 16, and the AC power is passed through the material having the bio-like conductivity.
  • the surface of the energizing means and the surface of the living body can be compared even if the insulation between the living body and its surroundings is somewhat insufficient compared to the conducting means using the conductive material of the conventional high-potential treatment device. It is difficult for electric discharge to occur during the period, and the occurrence of pain due to electric discharge can be reduced.
  • the first material or the second It is desirable to use a third material that has a lower conductivity than this material.
  • a third material include synthetic rubber and silicon.
  • the electrical resistance value of the third material is preferably 1 O k Q / cm 2 or more.
  • the energizing means 16 can have a sufficient thickness and a free shape. For this reason, it is easy to give the energization means 16 a pressure (load) dispersion function, and as a result, the adhesion to the living body can be improved, so that an AC voltage can be stably applied over a long period of time. Application efficiency and application stability can be improved.
  • the energization means 16 can have any shape, for example, a chair type, a chair cover type, a seat chair type, a seat chair cover type, a regular seat type, a regular seat cover type, Cushion type, Cushion cover type, Mattress type for whole body, Mattress type for whole body, Bar head type, Headrest type, Headrest cover type, Cushion type, Cushion cover type, Pillow type, Pillow cover type, Auxiliary pillow type, Auxiliary pillow cover type Upper body pillow type, upper body pillow cover type, body pillow type, body pillow cover type, bed type, sofa type, etc.
  • the energizing means 16 is shaped like an upper-body pillow as shown in Fig. 2, so that the cervical spine is bent back in the supine position (takes a posture in which the chin is up). It is possible to raise the head horizontally without urging the cervical vein, which can be expected to improve circulation at the same site.
  • the flexor muscles around the upper thoracic vertebra can be moderately stretched with a slight jaw pulling posture, so the jaw is raised, the cervical vertebra and the upper thoracic vertebra are bent forward, so-called “pox-back” poor posture
  • the correction effect is also expected.
  • Such mild elevation of the head and neck and correction of poor posture can be expected to improve hard intuition, muscle pain, or stiff shoulders in the muscle groups around the neck and shoulders.
  • FIG. 3 is a view showing another modification of the energization means, (A) is a schematic side view thereof, and (B) is a schematic plan view thereof.
  • the energization means 30 shown in FIG. 3 has an upper body pillow cover type structure, and, like the energization means 16, the head portion 3 OA that contacts the living body head, and the living body thoracic vertebra For thoracic vertebrae in contact with 3 0 B Thus, the energizing section 30 C configured is provided, and the same effect as that of the energizing means 16 described above can be obtained.
  • the energizing means 30 has a hollow structure, and a pillow body made of, for example, polyurethane foam is accommodated in the hollow portion.
  • the energizing means 30 is formed such that the thoracic vertebra site 30 B is narrower than the head portion 3 OA. As a result, the head and neck can be appropriately held even in the lateral position by turning over.
  • Figs. 4 to 9 are diagrams showing still another modification of the energization means, (A) is a schematic perspective view thereof, (B) is a schematic side view thereof, and (C) is a schematic plan view thereof. It is.
  • the energizing means 40 shown in FIG. 4 includes a flat auxiliary pillow-shaped energizing portion 40 C.
  • the energizing means 50 shown in FIG. 5 has a headless energizing section 50 C having a rectangular bottom surface.
  • the energizing means 60 shown in FIG. 6 has a headrest cover type energizing part 60 C having a rectangular bottom surface.
  • the energizing means 70, 80, and 90 shown in 8 and 9 are pillow-shaped energizing portions 70 0 C, 80, respectively, having bottom surfaces that are substantially rectangular, substantially T-shaped, and substantially heart-shaped. C and 90C.
  • the pillow-shaped energizing means that mainly supports the neck from the dorsal side in the supine position, such as 70, 80, and 90, has a transition from the cervical spine to the head and neck.
  • the voltage measuring means 18 is a voltage value of a portion of the energization means 16 that contacts the living body, that is, an effective voltage value of an alternating voltage actually applied to the living body ("effective applied voltage” Value ")".
  • the AC voltage generated by the voltage generation means 14 attenuates at various levels before being applied to the living body, but the voltage measurement means 1 8 can grasp the effective applied voltage value.
  • the voltage measurement means 1 8 can grasp the effective applied voltage value.
  • the voltage measuring means 18 measures the effective applied voltage value.
  • the control unit 28 of the voltage generating means 14 compares the effective applied voltage value obtained by the voltage measuring means 18 with the set target applied voltage value, and if there is a difference between them, Increase or decrease the output to energization means 16 to correct. By repeating this procedure, errors due to various factors such as voltage decay can be removed, and the accurate application of the target voltage value to the living body can be achieved.
  • the increase device 10 is configured so that an alternating voltage is applied to the living body by the energization unit 16C of the energization unit 16 together with the voltage measurement unit 18 or instead of the voltage measurement unit 18.
  • An electric field measuring means 19 for measuring an effective electric field value (“effective applied electric field value”) actually applied to the living body may be provided.
  • the target applied voltage can be accurately determined by correcting the output of the voltage generating means 14 based on this information. It can be applied to a living body.
  • the voltage generation unit 14 automatically corrects the voltage applied to the living body.
  • the effective voltage value measured by the voltage measurement unit 18 is used as the operation unit of the voltage generation unit 14.
  • a configuration may be adopted in which the applied voltage to the living body is corrected by displaying the value 20 and manually changing the set value of the applied voltage.
  • the voltage measuring unit 18 is configured as a member independent of the voltage generating unit 14, but the voltage measuring unit 18 is a part of the voltage generating unit 14. May be incorporated in the voltage generation means 14.
  • the increasing device 10 does not necessarily have the voltage measuring means 18 and is preset or specified based on the actual value or the like when output from the voltage generating means 14
  • the voltage measurement means 18 may be omitted by increasing the output voltage attenuation level calculated according to this algorithm and outputting it.
  • the posture of the user M when using the increase device 10 is, for example, a lying posture as shown in FIGS. 10 (A) to (D) or a chair as shown in FIG. Can be illustrated.
  • User M lies down in contact with energizing means 16.
  • the energizing means 16 is connected to the voltage generating means 14, and by operating the increasing device 10 by the operation unit 20 (see FIG. 1) of the voltage generating means 14, the AC voltage is supplied to the user M. Can be applied.
  • the part of the body to which the AC voltage is to be applied is not particularly limited, and is applied to the whole body. It may be applied to a specific site, but is preferably considered as a central region for producing brain-derived neurotrophic factor as shown in FIGS. 7 (B) to (D) It is preferably applied to the head and neck, and particularly preferably, the headrest type (Fig. 10 (B)), upper body pillow type (Fig. 10 (C)) or pillow type (Fig. 10 (D)) energizing means 1 6 should be applied to the head and neck.
  • Fig. 1 1 On the other hand, as shown in Fig. 1 1, the user M is in the posture of sitting on the chair C and the increase device When using 1 0, place an insulating mat 2 8 on the floor Y to insulate the current-carrying means 16 from the ground, and place the chair C on it. The user M sits down on the chair C so as to contact the energizing means 16.
  • the energizing means 1 6 is connected to the voltage generating means 14 and the high voltage is applied to the user M by operating the increasing device 10 by the operation unit 20 of the voltage generating means 14. Can do.
  • the energizing means 16 may be disposed at a position in contact with the user M.
  • the energizing means 16 may be disposed on the seat surface of the chair C as shown in FIG.
  • the chair C if the chair C is on the back, it may be placed on a footrest.
  • the voltage value of the alternating voltage applied to the living body by the increase device 10 may be constant during the period of loading on the living body, but may vary regularly or irregularly in the voltage value range. Good. Further, the frequency of the AC voltage is not particularly limited, and for example, a frequency of 50 to 60 Hz can be applied.
  • the time for applying the AC voltage is not particularly limited, it is preferable to apply a certain time every day (for example, about 20 minutes to 4 hours in total per day), and this is continuously performed for at least one week to two months or more. It is even better to do this.
  • the present inventor has found that brain-derived neurotrophic factor increases by exposing a living body to a high voltage or placing it in a high electric field. However, if a high voltage continues to be applied to the living body, it has been found that although the brain-derived neurotrophic factor increases in the body for a certain period of time, the effect does not necessarily continue and the effect decreases over time. Research has found that by applying an effective applied voltage or effective applied electric field value in a specific area to a living body, the brain-derived neurotrophic factor is increased continuously over a long period of time in the living body.
  • the increase device 10 is used to improve cranial nerve function, improve memory ability or prevent and improve dementia, treat ischemic brain damage, decrease motivation, depression, depression mood disorder or Based on these, various symptoms are improved and appetite is suppressed.
  • the effective voltage applied to the living body by means of energization means 16 is 3.5 to 5.2 kV, preferably 3. It is preferably controlled to be 7 to 5.2 kV, or an effective applied electric field value of 15 to 22 kV / m, preferably 16 to 22 kV / m.
  • the brain-derived neurotrophic factor is increased continuously over a long period (P ⁇ 0. 05 Cannot continuously show significant difference) and cannot achieve the above therapeutic objectives.
  • the application of an alternating voltage to the living body by the energizing means 16 is effective. 3.5 to 4.3 kV, preferably 3.7 to 4.3 kV, or an effective applied electric field value of 15 to 19 kV / m, preferably 16 to 19 kV / m It is preferable to be controlled in this way. If the effective applied voltage value or effective applied electric field value of the alternating voltage applied to the living body is outside the above range, blood glucose is increased by continuously increasing the brain-derived neurotrophic factor in the blood over a long period of time. It cannot be reduced and the above therapeutic purpose cannot be achieved.
  • the electric field density generated in the cage space is 15 kV / m or 580 OV when the effective applied voltage value is 3500 V in the absence of the mouse. At times, it is 25 kV / m, and the presence of a living body in these electric fields generates a unique induced current inside the living body. This in vivo induced current (density) is thought to increase BDNF in vivo.
  • the specific application time and number of times were set to daily for 5 hours once a day, 1-2 weeks, or 1-24 weeks.
  • the brain was removed under general anesthesia from mice to which this alternating high potential was applied for various periods, and the brain content of brain-derived neurotrophic factor (BD NF), a kind of neurotrophic factor, and the blood concentration were determined. Measurement was performed using ELISA.
  • BD NF brain-derived neurotrophic factor
  • each analysis means that is, the amount of BD NF in the brain, the amount of BD NF in the blood, the escape time in the water maze test, the cerebral infarction volume after transient local cerebral ischemia, or Regarding the change in body weight, any group of 1, 3, 6, 1 or 2 weeks, which was subjected to high potential stimulation (treatment), or the control group which was subjected to OV stimulation for the same period, these stimulation periods were the same Statistically significant difference test (one-way ANOVA) is performed on all the groups, and if significant difference is observed, each treatment group and control are performed by Ho I mS idak test. Comparison with the group was made, and a P value of less than 0.05 was judged as “significantly different”.
  • results corresponding to the 3700 V, 4300 V, and 5200 V stimulation (treatment) periods shown in the table below are the results after high-potential stimulation (treatment) of 3500 V and 5800 V, respectively. Based on the obtained data, the estimated value calculated by the weighted average is shown.
  • FIG. 12 is a graph showing changes in brain content of BD NF
  • Fig. 13 is a graph showing changes in blood concentration.
  • symbol A in Fig. 1 2 and Fig. 1 3 gave a high potential stimulus of 5800 V
  • symbol B gave a high potential stimulus of 5200 V
  • symbol C gave a high potential stimulus of 4300 V
  • the symbol D is 3700 V high potential
  • the symbol E is a graph when a high-potential stimulus of 350 OV is given (the same applies to FIGS. 14 to 16 below).
  • the effective voltage value of the AC voltage should be set to 3500 V to 4300 V, preferably 3700 V to 430 OV. Was shown to be preferred.
  • FIG. Fig. 14 is a graph showing the change in escape time.
  • mice were used. From the difference in body weight between humans and mice, it can be considered that 12 weeks of mice corresponds to about 12 years of baboons. Therefore, from the results of this experiment, it can be expected that humans will maintain the memory enhancement effect for a period of 12 years or several times as long.
  • BD NF is thought to increase brain function by being involved in neurite growth and synaptic modification, but the weight difference between humans and mice has reached 2000 times, and humans are more advanced. Has a well-developed brain.
  • the induced current generated in the living body due to the potential stimulation is a stimulus for increased production of BDNF, but it is assumed that the nervous system cell membrane having a potential difference inside and outside is the target to receive this induced current stimulation. Since humans have a larger total cell surface area than mice, they can be considered more sensitive to potential stimuli. In this case, high-potential stimulation that lasts for 5 hours per day in mice may be comparable to 1 to several hours per day or less in humans.
  • FIG. Fig. 15 is a graph showing changes in cerebral infarction volume.
  • Fig. 16 is a graph showing changes in mouse body weight.
  • mice were used. From the weight difference between humans and mice, 12 weeks of mice is considered to correspond to approximately 12 years of baboons. Therefore, from the results of this experiment, humans can expect to maintain the weight-loss effect for a long period of 12 years or longer.
  • the effective voltage value of the AC voltage is 3500V to 4300 for the prevention and improvement of metapolitic syndrome that causes weight loss and causes obesity, diabetes, hypertension, or hyperlipidemia. It was shown that setting to V is preferable.
  • the BD NF increasing device or the increasing method for the purpose of improving is 3700V to 5200V, 3700V to 4300V
  • Use of AC effective applied voltage values of 4300 V to 5200 V, 3500 V to 5200 V, or 3500 V to 4300 V is expected to demonstrate their effectiveness over a longer period of time, and more to the living body. It was shown to be a potential level that seems to work safely.
  • a brain-derived neurotrophic factor in vivo is applied by applying an AC voltage having a specific voltage value to the living body. Therefore, the brain-derived neurotrophic factor can be continuously increased over a long period of time in vivo.
  • the brain-derived neurotrophic factor increasing device and the brain-derived neurotrophic factor increasing method of the present invention include humans, horses, ilka, lions, elephants, tigers, dogs, pigs, hedges, monkeys, and the like. Improvement of cranial nerve functions such as memory ability, prevention of dementia, elimination of ischemic brain damage, depression, depression mood disorder and various symptoms based on them, obesity, diabetes, hypertension, Alternatively, it can be suitably used for the prevention and improvement of metapolytic syndrome that causes hyperlipidemia and the like.
  • FIG. 1 is a block diagram showing the main configuration of a brain-derived neurotrophic factor increasing device according to the present embodiment.
  • FIG. 2 is a diagram showing the energization means in this embodiment, (A) is a schematic side view thereof (B) is a schematic plan view thereof.
  • FIG. 3 is a view showing a modification of the energizing means, (A) is a schematic side view thereof, and (B) is a schematic plan view thereof.
  • FIG. 4 is a view showing another modification of the energization means, (A) is a schematic perspective view thereof.
  • (B) is a schematic side view thereof, and (C) is a schematic plan view thereof.
  • FIG. 5 is a view showing another modification of the energization means, (A) is a schematic perspective view thereof.
  • (B) is a schematic side view thereof, and (C) is a schematic plan view thereof.
  • FIG. 6 is a view showing another modification of the energization means, (A) is a schematic perspective view thereof.
  • (B) is a schematic side view thereof, and (C) is a schematic plan view thereof.
  • FIG. 7 is a view showing another modification of the energization means, (A) is a schematic perspective view thereof.
  • (B) is a schematic side view thereof, and (C) is a schematic plan view thereof.
  • FIG. 8 is a view showing another modification of the energization means, (A) is a schematic perspective view thereof.
  • (B) is a schematic side view thereof, and (C) is a schematic plan view thereof.
  • FIG. 9 is a view showing another modification of the energization means, (A) is a schematic perspective view thereof.
  • (B) is a schematic side view thereof, and (C) is a schematic plan view thereof.
  • FIG. 10 is a diagram showing a use state of the brain-derived neurotrophic factor increasing device.
  • FIG. 11 is a diagram showing another use state of the brain-derived neurotrophic factor increasing device.
  • FIG. 12 is a graph showing changes in brain content of BDN F.
  • FIG. 13 is a graph showing changes in blood concentration.
  • FIG. 14 is a graph showing changes in escape time.
  • FIG. 15 is a graph showing changes in cerebral infarction volume.
  • FIG. 16 is a graph showing changes in mouse body weight.
  • Voltage generation means 1 6, 30, 40, 50, 60, 70, 80, 90 Current supply means 1 6 A Cable 1 6 B Electrode part 1 6 C, 30C , 40C, 50C, 60C, 70C, 80C, 90C Current-carrying part 1 8 Voltage measurement means 20 Operation part 22 ON / OFF switching part 24 High-voltage generation circuit 26 Temperature control part 28 Control part 28 Insulation mat 30 A Head part 3 OB Thoracic part C Chair M User Y Floor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)

Abstract

L'invention concerne un procédé visant à augmenter le facteur neurotrophe lié au cerveau, le facteur neurotrophe lié au cerveau pouvant être augmenté de manière continue dans un corps vivant pendant une longue période de temps, et un appareil augmentant le facteur neurotrophe lié au cerveau. L'invention concerne donc un appareil (10) augmentant le facteur neurotrophe lié au cerveau comprenant : une unité de formation de tension (14) permettant de former une tension de courant alternatif présentant un niveau de tension spécifique ; une unité conductrice (16) permettant d'appliquer la tension de courant alternatif formée par l'unité de formation de tension (14) à un corps vivant pour ainsi augmenter un facteur neurotrophe lié au cerveau dans le corps vivant ; et une unité de mesure de tension (18) permettant de mesurer le niveau de tension efficace de la tension de courant alternatif appliquée en pratique au corps vivant par l'unité conductrice (16).
PCT/JP2007/000830 2006-08-01 2007-08-01 appareil augmentant le facteur neurotrophe lié au cerveau et procédé visant à augmenter le facteur neurotrophe lié au cerveau WO2008015793A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008527659A JP5272164B2 (ja) 2006-08-01 2007-08-01 脳由来神経栄養因子増加装置および脳由来神経栄養因子増加方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006209423 2006-08-01
JP2006-209423 2006-08-01

Publications (1)

Publication Number Publication Date
WO2008015793A1 true WO2008015793A1 (fr) 2008-02-07

Family

ID=38996979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/000830 WO2008015793A1 (fr) 2006-08-01 2007-08-01 appareil augmentant le facteur neurotrophe lié au cerveau et procédé visant à augmenter le facteur neurotrophe lié au cerveau

Country Status (2)

Country Link
JP (1) JP5272164B2 (fr)
WO (1) WO2008015793A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010264242A (ja) * 2009-04-14 2010-11-25 Minato Ikagaku Kk 生体電位制御式電位治療器
WO2015111656A1 (fr) * 2014-01-24 2015-07-30 独立行政法人情報通信研究機構 Dispositif de sortie de détection de champ électrique, système et procédé de réglage de champ électrique

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02126861A (ja) * 1988-10-05 1990-05-15 Niels Kornerup 電気刺激による傷治療装置
JPH11114073A (ja) * 1997-10-09 1999-04-27 Fact:Kk 治療用導子及び該治療用導子を使用した理学療法用器械機具
JP2002233585A (ja) * 2001-02-09 2002-08-20 Matsushita Electric Works Ltd 生体用電極材
JP3091848U (ja) * 2002-08-02 2003-02-21 中山 登稔 低周波治療器の皮膚接触電極体
JP2005511164A (ja) * 2001-12-03 2005-04-28 メドトロニック・インコーポレーテッド 一定の送出エネルギー用の任意波形の制御
WO2006035622A1 (fr) * 2004-09-28 2006-04-06 Japan Health Sciences Foundation Procédé de fabrication de facteur de nutrition nerveuse in vivo utilisant un potentiel élevé alternatif et dispositif de fabrication de facteur de nutrition nerveuse in vivo

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02126861A (ja) * 1988-10-05 1990-05-15 Niels Kornerup 電気刺激による傷治療装置
JPH11114073A (ja) * 1997-10-09 1999-04-27 Fact:Kk 治療用導子及び該治療用導子を使用した理学療法用器械機具
JP2002233585A (ja) * 2001-02-09 2002-08-20 Matsushita Electric Works Ltd 生体用電極材
JP2005511164A (ja) * 2001-12-03 2005-04-28 メドトロニック・インコーポレーテッド 一定の送出エネルギー用の任意波形の制御
JP3091848U (ja) * 2002-08-02 2003-02-21 中山 登稔 低周波治療器の皮膚接触電極体
WO2006035622A1 (fr) * 2004-09-28 2006-04-06 Japan Health Sciences Foundation Procédé de fabrication de facteur de nutrition nerveuse in vivo utilisant un potentiel élevé alternatif et dispositif de fabrication de facteur de nutrition nerveuse in vivo

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010264242A (ja) * 2009-04-14 2010-11-25 Minato Ikagaku Kk 生体電位制御式電位治療器
WO2015111656A1 (fr) * 2014-01-24 2015-07-30 独立行政法人情報通信研究機構 Dispositif de sortie de détection de champ électrique, système et procédé de réglage de champ électrique
JP2016055186A (ja) * 2014-01-24 2016-04-21 株式会社白寿生科学研究所 電界調整システム及び電界調整方法
CN107015071A (zh) * 2014-01-24 2017-08-04 株式会社白寿生科学研究所 电场感测输出装置、电场调整***以及电场调整方法
TWI647459B (zh) * 2014-01-24 2019-01-11 日商白壽生科學研究所股份有限公司 Electric field adjustment system and electric field adjustment method

Also Published As

Publication number Publication date
JPWO2008015793A1 (ja) 2009-12-17
JP5272164B2 (ja) 2013-08-28

Similar Documents

Publication Publication Date Title
Bogie et al. Effects of regular use of neuromuscular electrical stimulation on tissue health.
Poulsen et al. Effect of transcutaneous electrical muscle stimulation on muscle volume in patients with septic shock
JP5366146B2 (ja) 経皮刺激による血圧安定化装置
Bogie et al. Long-term prevention of pressure ulcers in high-risk patients: a single case study of the use of gluteal neuromuscular electric stimulation
Liu et al. Pressure changes under the ischial tuberosities of seated individuals during sacral nerve root stimulation
US4727878A (en) Functional electrical stimulation for pressure sore inhibition
Chevalier Grounding the human body improves facial blood flow regulation: results of a randomized, placebo controlled pilot study
Park et al. Comparison between neuromuscular electrical stimulation to abdominal and back muscles on postural balance in post-stroke hemiplegic patients
JP5272164B2 (ja) 脳由来神経栄養因子増加装置および脳由来神経栄養因子増加方法
Curtis et al. The effects of intermittent electrical stimulation on the prevention of deep tissue injury: varying loads and stimulation paradigms
KR101378163B1 (ko) 멀티자세 교정기
CN106669042A (zh) 风湿治疗复健专用椅
Arias et al. An alternating pressure sequence proposal for an air-cell cushion for preventing pressure ulcers
Liu et al. Pressure changes under the ischial tuberosities during gluteal neuromuscular stimulation in spinal cord injury: a comparison of sacral nerve root stimulation with surface functional electrical stimulation
US20110112604A1 (en) Mitigation of pressure ulcers using electrical stimulation
AU2008229611B2 (en) System for electrically stimulating muscles or nerves
CN213760225U (zh) 一种带有灭菌装置的高电位治疗仪
Yoon et al. Foot pressure and trunk muscle activity during reaching tasks performed by seated hemiplegia patients
Zaidi et al. Retrolisthesis: an update
KR102170267B1 (ko) 고주파 치료기
JPWO2006035622A1 (ja) 交流高電位を用いた生体内神経栄養因子産生方法及び生体内神経栄養因子産生装置
KR102306632B1 (ko) 미세전류를 이용한 혈액순환장치
CN210228423U (zh) 一种脊椎曲度牵引器
Patra et al. Effectiveness of thoracic spine manipulation in conjunction with cranial base release technique on pain and range of motion in patients with mechanical neck pain.
KR20170006465A (ko) 다목적 마사지용 지압기

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07790319

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008527659

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07790319

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)